I'm replying to myself again re the ASSURE trial Sept 3rd post hocs.

Here is the danger of top line results. As was pointed out while Crestor + rvx-208 achieved highly statistically significant PAV regression of -1.43% vs a target of -0.6% it was the Lipitor group in which PAV progressed at a non statistically significant rate of 0.19% and thus the average of the 2 did not achieve significance overall. Caution here with my interpretation because the PAV with -1.43% was done on a sub group.

Either way top line findings can be seriously damaging as  many of us have lived with. Let us hope BoM toplines are more well thought through and embellished to yield a more full picture e.g. total, Crestor subset, Lipitor subset.

OK this is well known old news so I will slap my own hands because I am sure I am now breaking Agoracom posting rules. I'll try to behave.

GLTA

Toinv